Table 3.

Outcomes in patients with NSCLC harboring uncommon EGFR mutations which are known to be resistance mechanisms to osimertinib.

Ethnicity	Gender	Age	Smoking status	Brain metastases	EGFR mutations			Afatinib treatment setting	Best response	TTF, months
Asian	F	55	–	Yes	G724S	Del19	–	Post osimertinib	PR	3.8+
Non-Asian	F	49	NS	Yes	G724S	Del19	–	Post osimertinib	–	3.0 a
Asian	F	64	NS	–	G724S	R776H	–	TKI naïve	SD	17.0 b
Asian	–	–	–	–	G724S	E746_S752delinsV	–	Post osimertinib	SD	Median 4.5
Asian	–	–	–	–	G724S	E746_S752delinsV	–	Post osimertinib	SD
Asian	–	–	–	–	G724S	E746_S752delinsV	–	Post osimertinib	SD
Asian	–	–	–	–	G724S	S768I	–	Osimertinib naïve	SD
Asian	–	–	–	–	G724S	S768I	Del19	Osimertinib naïve	SD
Asian	–	–	–	–	G724S	Exon20ins	–	Osimertinib naïve	SD
Asian	M	–	–	–	G724S	E746_S752delinsV	–	Post osimertinib	SD	2.7
Asian	F	–	–	–	G724S	E746_S752delinsV	–	Post osimertinib	SD	6.1
Non-Asian	M	49	–	Yes	G724S	Del19	–	Post osimertinib	PR	8.0+ a
Non-Asian	M	51	NS	Yes	G724S	Del19	–	Post osimertinib	SD	10.0+
Asian	F	65	–	Yes	L718Q	L858R	(BRAF)	Post osimertinib	SD	4.0
–	F	62	S	–	L718Q	L718V	L858R	Post osimertinib	PR	4.5+
Asian	F	69	NS	–	L718Q	L858R	–	Post osimertinib	PR	4.0
Asian	F	65	NS	–	L718V	L858R	–	Post osimertinib	PR	6.0+
–	–	–	–	–	L718V	L858R	–	Post osimertinib	SD	15.0
–	–	–	–	–	C797S	L858R	V765L	Post osimertinib	SD	4.0

EGFR, epidermal growth factor receptor; NS, never smoker; NSCLC, non-small-cell lung cancer; PR, partial response; S, smoker; SD, stable disease; TTF, time to treatment failure.

^aReceived afatinib combined with osimertinib.

^bReceived afatinib combined with bevacizumab.